Medco Decision To Avoid “At-Risk” Medicare Rx Plans Is “Premature,” CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PBMs should wait to see Part D implementing regs before deciding whether to offer a stand-alone drug plan, CMS’ Trysla says. PCMA and CMS Administrator McClellan discuss Medco’s position on the drug benefit.
You may also be interested in...
Medco Will Work With CMS On Medicare Rules: Backpedaling From "Fallback"?
Medco has been asked by CMS to offer constructive ideas to help make private drug insurance work, and company says it intends to do that in commenting on Part D regulations. However, CEO suggests Medco remains most interested in working under Medicare Advantage and through "fallback" plan.
Medco Will Work With CMS On Medicare Rules: Backpedaling From "Fallback"?
Medco has been asked by CMS to offer constructive ideas to help make private drug insurance work, and company says it intends to do that in commenting on Part D regulations. However, CEO suggests Medco remains most interested in working under Medicare Advantage and through "fallback" plan.
“Fallback” Plan Will Be Main Medicare Rx Program, Medco Predicts
The private sector is unlikely to offer stand-alone drug insurance plans under Medicare in 2006, Medco CEO David Snow predicted during the Goldman Sachs conference in Laguna Niguel, Calif. June 9